vs
Side-by-side financial comparison of Civeo Corp (CVEO) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Civeo Corp is the larger business by last-quarter revenue ($161.6M vs $103.7M, roughly 1.6× Twist Bioscience Corp). Civeo Corp runs the higher net margin — -4.0% vs -29.4%, a 25.4% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs 7.1%). Civeo Corp produced more free cash flow last quarter ($14.5M vs $-34.8M).
The Civeo Corporation is an American accommodation services multinational corporation. It is a spin-off of Oil States International. It is a public company listed on the New York Stock Exchange.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
CVEO vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $161.6M | $103.7M |
| Net Profit | $-6.5M | $-30.5M |
| Gross Margin | 22.7% | 52.0% |
| Operating Margin | -0.1% | -31.7% |
| Net Margin | -4.0% | -29.4% |
| Revenue YoY | 7.1% | 16.9% |
| Net Profit YoY | 58.1% | 3.4% |
| EPS (diluted) | $-0.58 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $161.6M | $103.7M | ||
| Q3 25 | $170.5M | — | ||
| Q2 25 | $162.7M | — | ||
| Q1 25 | $144.0M | — | ||
| Q4 24 | $151.0M | — | ||
| Q3 24 | $176.3M | — | ||
| Q2 24 | $188.7M | — | ||
| Q1 24 | $166.1M | — |
| Q4 25 | $-6.5M | $-30.5M | ||
| Q3 25 | $-455.0K | — | ||
| Q2 25 | $-3.3M | — | ||
| Q1 25 | $-9.8M | — | ||
| Q4 24 | $-15.4M | — | ||
| Q3 24 | $-5.1M | — | ||
| Q2 24 | $8.2M | — | ||
| Q1 24 | $-5.1M | — |
| Q4 25 | 22.7% | 52.0% | ||
| Q3 25 | 25.7% | — | ||
| Q2 25 | 25.3% | — | ||
| Q1 25 | 20.4% | — | ||
| Q4 24 | 18.6% | — | ||
| Q3 24 | 21.4% | — | ||
| Q2 24 | 25.4% | — | ||
| Q1 24 | 21.5% | — |
| Q4 25 | -0.1% | -31.7% | ||
| Q3 25 | 4.1% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | -3.8% | — | ||
| Q4 24 | -6.7% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 6.9% | — | ||
| Q1 24 | -1.1% | — |
| Q4 25 | -4.0% | -29.4% | ||
| Q3 25 | -0.3% | — | ||
| Q2 25 | -2.0% | — | ||
| Q1 25 | -6.8% | — | ||
| Q4 24 | -10.2% | — | ||
| Q3 24 | -2.9% | — | ||
| Q2 24 | 4.4% | — | ||
| Q1 24 | -3.1% | — |
| Q4 25 | $-0.58 | $-0.50 | ||
| Q3 25 | $-0.04 | — | ||
| Q2 25 | $-0.25 | — | ||
| Q1 25 | $-0.72 | — | ||
| Q4 24 | $-1.04 | — | ||
| Q3 24 | $-0.36 | — | ||
| Q2 24 | $0.56 | — | ||
| Q1 24 | $-0.35 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.4M | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $174.4M | $456.1M |
| Total Assets | $477.4M | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.4M | $197.9M | ||
| Q3 25 | $12.0M | — | ||
| Q2 25 | $14.6M | — | ||
| Q1 25 | $28.4M | — | ||
| Q4 24 | $5.2M | — | ||
| Q3 24 | $17.9M | — | ||
| Q2 24 | $7.4M | — | ||
| Q1 24 | $16.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $43.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $174.4M | $456.1M | ||
| Q3 25 | $182.5M | — | ||
| Q2 25 | $209.4M | — | ||
| Q1 25 | $220.7M | — | ||
| Q4 24 | $236.4M | — | ||
| Q3 24 | $282.2M | — | ||
| Q2 24 | $297.4M | — | ||
| Q1 24 | $297.4M | — |
| Q4 25 | $477.4M | $638.1M | ||
| Q3 25 | $491.1M | — | ||
| Q2 25 | $508.8M | — | ||
| Q1 25 | $423.8M | — | ||
| Q4 24 | $405.1M | — | ||
| Q3 24 | $477.6M | — | ||
| Q2 24 | $483.2M | — | ||
| Q1 24 | $513.1M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.18× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $19.3M | $-24.8M |
| Free Cash FlowOCF − Capex | $14.5M | $-34.8M |
| FCF MarginFCF / Revenue | 8.9% | -33.5% |
| Capex IntensityCapex / Revenue | 3.0% | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.3M | $-24.8M | ||
| Q3 25 | $13.8M | — | ||
| Q2 25 | $-2.3M | — | ||
| Q1 25 | $-8.4M | — | ||
| Q4 24 | $9.5M | — | ||
| Q3 24 | $35.7M | — | ||
| Q2 24 | $32.4M | — | ||
| Q1 24 | $6.0M | — |
| Q4 25 | $14.5M | $-34.8M | ||
| Q3 25 | $8.2M | — | ||
| Q2 25 | $-6.8M | — | ||
| Q1 25 | $-13.7M | — | ||
| Q4 24 | $1.8M | — | ||
| Q3 24 | $28.2M | — | ||
| Q2 24 | $27.0M | — | ||
| Q1 24 | $372.0K | — |
| Q4 25 | 8.9% | -33.5% | ||
| Q3 25 | 4.8% | — | ||
| Q2 25 | -4.2% | — | ||
| Q1 25 | -9.5% | — | ||
| Q4 24 | 1.2% | — | ||
| Q3 24 | 16.0% | — | ||
| Q2 24 | 14.3% | — | ||
| Q1 24 | 0.2% | — |
| Q4 25 | 3.0% | 9.6% | ||
| Q3 25 | 3.3% | — | ||
| Q2 25 | 2.8% | — | ||
| Q1 25 | 3.7% | — | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 4.2% | — | ||
| Q2 24 | 2.8% | — | ||
| Q1 24 | 3.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 3.93× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CVEO
Segment breakdown not available.
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
